Treatment of Advanced (FIGO Stage III or IV) Fallopian Tube Carcinoma in Women Eligible for Optimal Surgical Debulking
This protocol addresses women with advanced fallopian tube carcinoma — FIGO stage III or IV — who have a high likelihood of achieving optimal surgical debulking and do not carry a high perioperative risk.
Clinical Scenario
Female patient with advanced (FIGO stage III or IV) fallopian tube carcinoma. A high likelihood of achieving optimal surgical debulking has been established, and perioperative risk is not elevated. NCCN recommends evaluation by a gynecologic oncologist, as optimal surgical debulking by a skilled physician is central to initial management of stage III or IV disease. ASCO supports primary cytoreductive surgery in this setting when the likelihood of optimal debulking is high and perioperative risk is acceptable.
Treatment Approach — partial overview
The structured regimen for this scenario includes targeted biological therapy options; complete eligibility criteria, sequencing, and all dosing details are available only in the full protocol.
References
DOI: 10.1200/JOP.18.00662
- National Comprehensive Cancer Network recommends that any woman with suspected epithelial ovarian cancer be evaluated by a gynecologic oncologist, because optimal surgical debulking by a skilled physician is central to the initial management of patients with advanced, stage III or IV disease.
- ASCO states that although primary cytoreductive surgery is preferred for patients with a high likelihood of achieving optimal debulking, women with high perioperative risk or a low likelihood of achieving optimal cytoreduction should receive neoadjuvant chemotherapy followed by possible interval surgery.
- To date, bevacizumab has been FDA approved for the following uses in epithelial ovarian cancer: in combination with carboplatin plus paclitaxel, followed by bevacizumab single agent for stage III or IV disease after initial surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent epithelial ovarian cancer after no more than two prior chemotherapy regimens; and in combination with carboplatin plus paclitaxel or carboplatin plus gemcitabine, followed by bevacizumab single agent, for platinum-sensitive recurrent epithelial ovarian cancer.
- Olaparib is approved as a treatment for patients with a germline BRCA mutation who have received at least three prior lines of chemotherapy.
- Rucaparib is similarly approved as a treatment after at least two prior lines of chemotherapy but in patients with a germline or a somatic BRCA mutation.
View source ↗